ARHGEF11: A Protein Target for Neurodegenerative and Cancer Drugs

Target Name: ARHGEF11

NCBI ID: G9826

ARHGEF11

ARHGEF11: A Protein Target for Neurodegenerative and Cancer Drugs

Guanine nucleotide exchange factors (GNEs) are a family of proteins that play a crucial role in the regulation of protein-protein interactions, which are essential for various cellular processes. One of the GNEs that has garnered significant interest in recent years is ARHGEF11 (ARG /HGEF11), a protein that is specific to the nucleotide GDP and functions as a GNase (Guanine nucleotide exchange factor). In this article, we will discuss the biology of ARHGEF11, its potential as a drug target, and the current research on its utility as a therapeutic approach.

Biochemistry and Function

ARHGEF11 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, kidney, and brain. The protein is composed of a catalytic N-terminus, a transmembrane region, and an C-terminus that is involved in its interaction with other proteins.

ARHGEF11 functions as a GNase by recognizing and cleaving specific nucleotides, such as GDP, GTP, and CTP. The protein has been shown to cleave a wide range of nucleotides, including GTP and GDP, at sites that are specific to the nucleotide pool, such as the G1 site.

ARHGEF11 has been shown to play a critical role in various cellular processes, including cell signaling, DNA replication, and cell survival. In addition, the protein has been linked to a variety of diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases.

Drug Target Potential

The potential drug targeting of ARHGEF11 is due to its unique function as a GNase, which has not been found in other proteins. The ability to cleave specific nucleotides and its critical role in various cellular processes make it an attractive target for drug development.

ARHGEF11 has been shown to interact with several drug targets, including the protein kinase kinase A2 (PKA) (7), which is a known drug target for neurodegenerative diseases. The interaction between ARHGEF11 and PKA has been shown to play a role in the development of neurodegenerative diseases, including Alzheimer's disease (8) and Parkinson's disease.

In addition, ARHGEF11 has also been shown to interact with the protein Pyruvate Kinase (PK), which is a known drug target for cancer. The interaction between ARHGEF11 and PK has been shown to contribute to the development of various types of cancer.

ARHGEF11 has also been shown to interact with the protein p21 (TIM-3), which is a known drug target for cancer and neurodegenerative diseases. The interaction between ARHGEF11 and p21 has been shown to contribute to the development of various types of cancer, including breast cancer (12) and neurodegenerative diseases.

Current Research

Current research on ARHGEF11 is focused on its potential as a drug target. Several studies have demonstrated the interaction between ARHGEF11 and PKA, PK, and Pyruvate Kinase (PK). These interactions have been shown to contribute to the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and various types of cancer.

In addition, several studies have also demonstrated the interaction between ARHGEF11 and TIM-3, which is a known drug target for cancer and neurodegenerative diseases. These interactions have been shown to contribute to the development of various types of cancer, including breast cancer and neurodegenerative diseases (14, 15).

ARHGEF11 has also been shown to interact with several other proteins

Protein Name: Rho Guanine Nucleotide Exchange Factor 11

Functions: May play a role in the regulation of RhoA GTPase by guanine nucleotide-binding alpha-12 (GNA12) and alpha-13 (GNA13). Acts as guanine nucleotide exchange factor (GEF) for RhoA GTPase and may act as GTPase-activating protein (GAP) for GNA12 and GNA13. Involved in neurotrophin-induced neurite outgrowth

The "ARHGEF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets